Evidence map›Paper›PMID 33994798›Full record

ArticleOncoTargets and therapy2021

Significant Benefits of Afatinib and Apatinib in a Refractory Advanced NSCLC Patient Resistant to Osimertinib: A Case Report.

Yuanyang Zhao, Yuxing Chen, Huaying Huang, Xi Li, Lin Shao, Hao Ding

Open access · goldAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in OncoTargets and therapy, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.0field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 7 citations in OpenAlex.

  1. Acquired multipleOncology letters · 2025
    Article
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Yuanyang Zhao *Department of Respiratory Disease, Affiliated People's Hospital of Jiangsu University, Zhenjiang, 212002, People's Republic of China.ORCID 0000-0001-9541-9434
Yuxing Chen *Department of Respiratory Disease, Affiliated People's Hospital of Jiangsu University, Zhenjiang, 212002, People's Republic of China.ORCID 0000-0002-1110-2411
Huaying HuangDepartment of Respiratory Disease, Affiliated People's Hospital of Jiangsu University, Zhenjiang, 212002, People's Republic of China.ORCID 0000-0002-3628-6480
Xi LiDepartment of Medicine, Burning Rock Biotech, Guangzhou, 510300, People's Republic of China.
Lin ShaoDepartment of Medicine, Burning Rock Biotech, Guangzhou, 510300, People's Republic of China.
Hao DingDepartment of Respiratory Disease, Affiliated People's Hospital of Jiangsu University, Zhenjiang, 212002, People's Republic of China.ORCID 0000-0002-5761-9280
Jiangsu University · CNBurning Rock Biotech (China) · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

EGFR-tyrosine kinase inhibitors (TKIs) have revolutionized the treatment for NSCLC. However, acquired drug resistance often occurs after treatment with EGFR-TKIs.

Indexed as

afatinibapatinibEGFR-mutantNSCLCTKI

Identifiers

PMID33994798
PMCPMC8114361
OpenAlexW3157987239

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.